| 标题 |
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet Haematology 作者:Hartmut Goldschmidt; Elias K Mai; Uta Bertsch; Roland Fenk; Eva Nievergall; et al 出版日期:2022-10-31 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)